174 related articles for article (PubMed ID: 33576936)
1. Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Ma XZ; Xia YH; Tian JH; Ma Y; Liu Y; Zhang P; Xu M
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):265-275. PubMed ID: 33576936
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.
Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Li Y; Xia YH; Liu Y; Tian JH; Zhang P
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):361-369. PubMed ID: 32006325
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
[TBL] [Abstract][Full Text] [Related]
4. Exenatide pharmacokinetics in healthy Chinese subjects.
Zhao X; Cui YM; Zhou Y; Zhang HL; Yeo KP; Linnebjerg H; Tham LS; Kothare P; Teng LL; Mace K; Soon D
Int J Clin Pharmacol Ther; 2008 Sep; 46(9):459-65. PubMed ID: 18793576
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y
Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Kothare PA; Linnebjerg H; Isaka Y; Uenaka K; Yamamura A; Yeo KP; de la Peña A; Teng CH; Mace K; Fineman M; Shigeta H; Sakata Y; Irie S
J Clin Pharmacol; 2008 Dec; 48(12):1389-99. PubMed ID: 19047364
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.
Ji L; Du Y; Xu M; Zhou X; Mo Z; Ma J; Li J; Li Y; Lin J; Wang Y; Yang J; Song W; Jin H; Pang S; Liu H; Li P; Liu J; Yao M; Li W; Jiang X; Shen F; Geng H; Zhou H; Ran J; Lei M; Du Y; Ye S; Guan Q; Lv W; Tan H; Chen T; Yang J; Qin G; Li S; Chen L
Diabetologia; 2021 May; 64(5):1066-1078. PubMed ID: 33687487
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Kolterman OG; Kim DD; Shen L; Ruggles JA; Nielsen LL; Fineman MS; Baron AD
Am J Health Syst Pharm; 2005 Jan; 62(2):173-81. PubMed ID: 15700891
[TBL] [Abstract][Full Text] [Related]
12. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Henry RR; Logan D; Alessi T; Baron MA
Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
[TBL] [Abstract][Full Text] [Related]
13. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
[TBL] [Abstract][Full Text] [Related]
14. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
17. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
Ambery PD; Klammt S; Posch MG; Petrone M; Pu W; Rondinone C; Jermutus L; Hirshberg B
Br J Clin Pharmacol; 2018 Oct; 84(10):2325-2335. PubMed ID: 29926478
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.
Jin J; Cui G; Mi N; Wu W; Zhang X; Xiao C; Wang J; Qiu X; Han M; Li Z; Wang L; Lu T; Niu H; Wu Z; Li J
Eur J Pharm Sci; 2023 Jun; 185():106448. PubMed ID: 37062422
[TBL] [Abstract][Full Text] [Related]
19. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
[TBL] [Abstract][Full Text] [Related]
20. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
